HER-2 profiling and targeting in prostate carcinoma.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The role of HER-2 (Human Epidermal growth factor Receptor 2) in prostate carcinoma remains unclear.
• This study investigated the feasibility of molecular profiling to correlate HER-2 expression with hormonal sensitivity and treatment response in prostate cancer patients.

Purpose of the Study:

• To explore the clinical effects of targeting HER-2 in prostate carcinoma.
• To determine the correlation between HER-2 expression, hormonal sensitivity, and the antitumor effects of trastuzumab and paclitaxel.

Main Methods:

• Patients with progressive androgen-dependent (AD) and androgen-independent (AI) prostate carcinoma were enrolled.
• HER-2 expression was assessed on pretreatment tissue. Patients were assigned to treatment groups based on HER-2 status and hormonal sensitivity.
• Treatment involved weekly trastuzumab, with paclitaxel added upon disease progression.

Main Results:

• Out of 130 screened patients, 23 were treated. Only the AI HER-2 negative arm completed due to limited HER-2 positive cases.
• All patients (100%) progressed on trastuzumab monotherapy within 12 weeks.
• HER-2 overexpression was primarily observed in AI metastatic samples (42%).

Conclusions:

• Trastuzumab is not effective as a single agent for HER-2 negative AI prostate tumors.
• HER-2 expression can vary between AD and AI states, necessitating metastatic tissue sampling for accurate profiling.
• Further development of trastuzumab for prostate cancer is contingent on improved methods for identifying HER-2 positive metastatic disease.